Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
The Efficacy of Hydroxychloroquine and Azithromycin Combination Therapy on Hospital Mortality in COVID 19 Pneumonia Patients
Özuygur Ermiş et al., Turkish Journal of Medical Sciences, doi:10.3906/sag-2009-64
Özuygur Ermiş et al., The Efficacy of Hydroxychloroquine and Azithromycin Combination Therapy on Hospital Mortality in COVID 19.., Turkish Journal of Medical Sciences, doi:10.3906/sag-2009-64
Aug 2021   Source   PDF  
  All Studies   Meta
Retrospective 370 hospitalized patients, 222 receiving HCQ+AZ and 148 receiving HCQ, showing mortality OR 0.61 [0.23-1.59], p = 0.31 for the addition of AZ.
Özuygur Ermiş et al., 4 Aug 2021, peer-reviewed, 13 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: 1 The Efficacy of Hydroxychloroquine and Azithromycin Combination Therapy on 2 Hospital Mortality in COVID 19 Pneumonia Patients 3 4 Abstract 5 6 Background/aim: Effective therapeutic approaches for SARS-CoV-2 pandemic are 7 urgently needed. Hydroxychloroquine (HCQ) alone or in combination with azithromycin 8 has been used in several countries, without any clear evidence. This study aimed to 9 determine the effectiveness and safety of hydroxychloroquine as compared to 10 hydroxychloroquine and azithromycin combination in patients with COVID-19 11 pneumonia. 12 13 Materials and methods: This retrospective study evaluated all patients admitted to two 14 university hospitals between 18 March and 20 May 2020 with the diagnosis of COVID- 15 19 pneumonia. Out of 496 patients, 370 met the eligibility criteria and were included in 16 the final analysis. The primary outcome was in-hospital mortality. Secondary outcomes 17 were time to recovery, presence of severe acute respiratory infection (SARI), the 18 requirement for oxygen therapy, and/or mechanical ventilation, length of hospital stay, 19 and adverse events. 20 21 Results: A total of 222 patients received hydroxychloroquine and 148 were treated with 22 HCQ and azithromycin combination. The in-hospital mortality rates were similar in the 23 two groups (10.8% vs. 6.8%, respectively, p=0.186). Additionally, the needs for oxygen 24 therapy, invasive mechanic ventilation (IMV) and intensive care unit (ICU) admission 1 25 were not different. The rate of the requirement of non-invasive mechanic ventilation 26 (NIV) was higher in patients receiving HCQ plus azithromycin (10.1% vs. 4.5%, 27 p=0.035). Time to recovery was 3.5 days in HCQ and 5.0 days in HCQ plus azithromycin 28 group (p<0.001). The median length of hospital stay was longer in patients with the 29 combination therapy (7.0 vs. 5.5 days, p<0.001). Amongst all patients, only 3 patients 30 developed electrocardiographic changes needing discontinuation of therapy. 31 Limitations: Observational design of the study is the main limitation. 32 33 Conclusions: The present findings suggest that adding azithromycin to HCQ is not 34 associated with any improvement in clinical outcome and mortality in patients with 35 COVID-19 pneumonia and supports the current knowledge not to include azithromycin 36 in the initial treatment of COVID-19. 37 38 Keywords: SARS-CoV-2, COVID-19, hydroxychloroquine, azithromycin, mortality, 39 COVID-19 pneumonia 40 41 42 43 44 45 46 47 48 2 49 50
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop